Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, vTv Therapeutics's Enterprise Value is €29.00 Mil.
vTv Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-14.36 Mil. Therefore, vTv Therapeutics's EV-to-OCF for today is -2.02.
The historical rank and industry rank for vTv Therapeutics's EV-to-OCF or its related term are showing as below:
STU:5VT0'
s EV-to-OCF Range Over the Past 10 Years
Min: -48.43 Med: -3.9 Max: -0.89
Current: -2.01
During the past 13 years, the highest EV-to-OCF of vTv Therapeutics was -0.89. The lowest was -48.43. And the median was -3.90.
STU:5VT0's EV-to-OCF is ranked worse than 59.32% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs STU:5VT0: -2.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
vTv Therapeutics's PE Ratio (TTM) for today is calculated as:
vTv Therapeutics's share price for today is €28.60.
vTv Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.899.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
vTv Therapeutics EV-to-OCF Related Terms
vTv Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5VT0 vs BDTX, VANI, TLSA: EV-to-OCF Comparison
For the Biotechnology subindustry, vTv Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's EV-to-OCF falls into.
vTv Therapeutics's current Enterprise Value is €29.00 Mil.
vTv Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (STU:5VT0) has a EV-to-OCF of -2.02 as of Sep. 07, 2026. According to the industry distribution chart, vTv Therapeutics ranks #834 out of 1406 companies in the Biotechnology industry, placing it in the top 59.3%.
Is vTv Therapeutics' EV-to-OCF too high?
vTv Therapeutics' current EV-to-OCF is -2.02. Based on the distribution chart, vTv Therapeutics ranks #834 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' EV-to-OCF compare to BDTX and VANI?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #834 out of 1406 companies for EV-to-OCF. This places vTv Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. vTv Therapeutics's current EV-to-OCF is -2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, vTv Therapeutics (STU:5VT0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.18, compared to a current price of €28.60 — trading 15788.9% above its estimated fair value. The current EV-to-OCF is -2.02. vTv Therapeutics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For vTv Therapeutics (STU:5VT0), the current EV-to-OCF is -2.02 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (STU:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be overvalued.
The current stock price of €28.60 is trading 15788.9% above its estimated GF Value™ of €0.18.
GuruFocus considers vTv Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:5VT0:
EV-to-OCF: -2.02
GF Value™: €0.18 vs. price of €28.60 (15788.9% above fair value)
No single metric tells the full story. See the STU:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
31GF Score
Get the complete analysis for STU:5VT0
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5VT0 has been successfully added to your 
